Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts.
Infections remain a common cause of morbidity and mortality among patients receiving antineoplastic chemotherapy. Over the past 30 years a number of techniques have been evaluated in an attempt to reduce the incidence of bacterial, fungal, and viral infections. Protective isolation, oral nonabsorbable antibiotics, and selective decontamination of the gastrointestinal tract have all been extensively evaluated. More recently, newer antimicrobial agents have been employed, such as quinolones, imidazoles, and recombinant monoclonal agents for modulation of the immune cascade. A critical review of the advantages and disadvantages of each of these methodologies is presented.
Hathorn
J W
JW
Department of Medicine, Duke Medical Center, Durham, North Carolina.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control; D006801:Humans; D007114:Immunization; D016867:Immunocompromised Host; D007239:Infections / Q000453:epidemiology / Q000276:immunology*; D009181:Mycoses / Q000517:prevention & control; D009369:Neoplasms / Q000276:immunology; D012307:Risk Factors; D014777:Virus Diseases / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents